Integrins — Explain integrins and cell-matrix adhesion concepts - Cell Biology

SECTION 1

Historical Context & Motivation

For much of the twentieth century, the extracellular matrix (ECM) was regarded as a relatively inert scaffold that merely filled space between cells. Researchers knew that tissues were held together by something more than direct cell-cell contacts, yet the molecular basis of adhesion between cells and their surrounding matrix remained elusive. The central question that drove decades of investigation was deceptively simple: how do cells sense, attach to, and respond to the complex meshwork of proteins and polysaccharides that surround them? Answering this question required identifying the transmembrane receptors responsible for mediating these interactions—receptors that ultimately came to be known as integrins.

The discovery of integrins arose from converging lines of research in immunology, developmental biology, and cell adhesion biochemistry. Early clues came from monoclonal antibody screens that blocked leukocyte adhesion and from the purification of fibronectin receptors on fibroblast surfaces. By the mid-1980s, it became clear that an entire superfamily of structurally related heterodimeric receptors existed, linking the extracellular matrix to the intracellular actin cytoskeleton. The timeline below traces the key milestones that built our modern understanding of integrin biology.

1973 • Fibronectin Identified

Richard Hynes and colleagues identify fibronectin as a major cell-surface glycoprotein that mediates attachment to collagen substrates, establishing that specific ECM-binding molecules exist on cell surfaces.

1984 • RGD Motif Discovered

Erkki Ruoslahti and Michael Pierschbacher demonstrate that the tripeptide sequence Arg-Gly-Asp (RGD) in fibronectin is the minimal recognition sequence for cell adhesion, providing the first molecular handle for understanding receptor specificity.

1986 • Integrin Superfamily Named

Richard Hynes coins the term integrin to describe these receptors, emphasizing their role in integrating the extracellular matrix with the intracellular cytoskeleton. Multiple α and β subunits are cloned and sequenced.

1990s • Inside-Out & Outside-In Signaling

Researchers establish that integrins engage in bidirectional signaling: intracellular signals activate integrins (inside-out), while ligand binding triggers downstream cascades (outside-in), connecting adhesion to gene expression, migration, and survival.

2001–2004 • Crystal Structures Resolved

X-ray crystallography of the αVβ3 integrin ectodomain reveals the bent-to-extended conformational switch, providing a structural basis for affinity regulation and inspiring therapeutic drug design.

The discovery of integrins resolved a fundamental gap in cell biology: it explained how cells physically grip the ECM, transmit mechanical force across the plasma membrane, and convert adhesion events into biochemical signals that control proliferation, differentiation, and apoptosis. Understanding integrins is essential for appreciating processes as diverse as wound healing, immune cell trafficking, embryonic development, and cancer metastasis.

SECTION 2

Core Principles & Definitions

Integrins are heterodimeric transmembrane glycoproteins composed of one α (alpha) subunit and one β (beta) subunit that associate non-covalently. In mammals, 18 α subunits and 8 β subunits combine to form 24 known integrin heterodimers, each with distinct ligand specificities and tissue distributions. The extracellular domains of both subunits cooperate to form the ligand-binding headpiece, while the short cytoplasmic tails connect to a constellation of adaptor and signaling proteins collectively known as the integrin adhesome. This architecture allows integrins to function as molecular bridges—simultaneously engaging ECM ligands like fibronectin, collagen, and laminin on the outside and the actin cytoskeleton on the inside.

Heterodimeric Architecture

Each integrin consists of one α subunit and one β subunit. The α subunit contributes a β-propeller domain for ligand recognition, while the β subunit provides the βI/βA domain and interfaces with cytoplasmic adaptors such as talin and kindlin.

Conformational Activation

Integrins exist in three conformational states: bent-closed (inactive), extended-closed (primed), and extended-open (active). This switch controls ligand-binding affinity and is regulated by both intracellular (inside-out) and extracellular (outside-in) signals.

Bidirectional Signaling

Inside-out signaling: talin binding to the β-subunit cytoplasmic tail induces extension and high-affinity ligand binding. Outside-in signaling: ligand engagement triggers clustering and activates FAK, Src, and downstream MAPK/PI3K pathways that regulate survival, migration, and proliferation.

Focal Adhesions

Upon activation and clustering, integrins nucleate multi-protein complexes called focal adhesions. These structures contain >150 proteins—including talin, vinculin, paxillin, and focal adhesion kinase (FAK)—that link integrins to actin stress fibers and serve as signaling hubs for mechanotransduction.

Ligand Specificity via RGD and Beyond

Many integrins recognize the RGD motif (Arg-Gly-Asp) found in fibronectin, vitronectin, and fibrinogen. Others bind collagen via the GFOGER sequence or laminin through distinct domains. The particular α/β combination dictates ECM specificity, ensuring tissue-appropriate adhesion.

✦

KEY TAKEAWAY

Think of integrins as rivets in the hull of a ship. The outer head of the rivet grips the hull plating (ECM), the shaft passes through the hull wall (plasma membrane), and the inner head is hammered flat against the frame (cytoskeleton). If the rivet is not properly set (inactive conformation), the plating can tear away under stress. Just as a rivet must be activated by hammering, integrins must undergo a conformational change before they can bear mechanical load between the cell and its matrix.

SECTION 3

Visual Explanation — Integrin Structure & Conformational States

The three major conformational states of integrin heterodimers. The bent-closed state (left) has the headpiece folded toward the membrane, keeping affinity low. The extended-closed state (center) is primed for ligand engagement. The extended-open state (right) exhibits maximal ligand-binding affinity. Talin and kindlin bind the β-subunit cytoplasmic tail to stabilize the active conformation.

The diagram above illustrates the central paradigm of integrin regulation. In the bent-closed conformation, the ligand-binding headpiece is folded back toward the membrane, physically occluding the binding site and keeping the receptor in a default low-affinity state. This is the predominant form on quiescent cells. During inside-out activation, the cytoplasmic protein talin binds the β-subunit tail, disrupting the salt bridge between the α and β tails and triggering a switchblade-like extension of the ectodomain. In the fully extended-open state, the hybrid domain in the β subunit swings outward, opening the headpiece and increasing ligand-binding affinity by several orders of magnitude. Binding of kindlin to the membrane-proximal portion of the β tail cooperates with talin to achieve full activation. Once ligand is engaged, outside-in signals propagate through focal adhesion assembly, triggering downstream cascades that regulate cell behavior.

SECTION 4

Molecular Mechanism of Cell-Matrix Adhesion

Integrin-mediated cell-matrix adhesion is not a binary on/off switch; it is a tightly regulated, multi-step process governed by thermodynamic equilibria, cooperative binding events, and mechanical feedback. Understanding the quantitative framework behind integrin adhesion helps explain why cells can both grip their matrix tenaciously during tissue remodeling and release that grip rapidly during migration.

Affinity and Avidity: Two Levels of Adhesion Regulation

Integrin adhesion strength is controlled at two levels. Affinity refers to the binding strength of a single integrin heterodimer for its ligand and is governed by the conformational state of the receptor. Avidity describes the overall strength of multiple integrin-ligand interactions acting cooperatively—determined by the density and clustering of active integrins on the cell surface. Even modest changes in single-molecule affinity can produce dramatic effects on macroscopic adhesion when amplified across thousands of clustered receptors.

DISSOCIATION CONSTANT

K_d = [Integrin][Ligand] / [Integrin·Ligand]

K_d = dissociation constant (M); lower K_d indicates higher affinity. Inactive integrins typically exhibit K_d values in the millimolar range; upon activation, K_d can decrease to the nanomolar range (≈ 10⁻⁹ M), representing a ~10⁶-fold increase in binding strength.

FRACTIONAL OCCUPANCY (LANGMUIR ISOTHERM)

θ = [L] / (K_d + [L])

θ = fraction of integrins bound to ligand; [L] = free ligand concentration (M). When [L] = K_d, exactly half the integrin population is ligand-occupied (θ = 0.5). This relationship assumes non-cooperative, single-site binding and provides a baseline model before considering clustering-dependent avidity effects.

Mechanotransduction and Catch Bonds

A remarkable feature of integrins is their ability to form catch bonds—bonds whose lifetime increases under moderate tensile force before eventually decreasing at high forces (transitioning to slip-bond behavior). This counterintuitive property means that physiological levels of mechanical stress actually strengthen the integrin-ECM connection, enabling cells to reinforce adhesion sites that bear load. Single-molecule force spectroscopy experiments on α₅β₁–fibronectin bonds have demonstrated peak bond lifetimes at forces around 10–30 pN, after which the bond transitions to slip-bond behavior and dissociates more rapidly.

BELL MODEL — FORCE-DEPENDENT UNBINDING RATE

k_off(F) = k_off⁰ × exp(F × x_β / k_B T)

k_off(F) = force-dependent off-rate; k_off⁰ = intrinsic off-rate at zero force; F = applied force (N); x_β = distance to the transition state along the reaction coordinate (m); k_BT = thermal energy (≈ 4.1 × 10⁻²¹ J at 37 °C). This slip-bond model predicts that applied force exponentially accelerates unbinding. The catch-bond behavior of integrins requires more complex two-pathway models.

ℹ

Why Catch Bonds Matter

Catch bonds enable a fundamental biological strategy: cells can selectively reinforce adhesions under load while allowing unstressed adhesions to turn over. This creates a mechanical feedback loop where traction forces generated by the actomyosin cytoskeleton promote integrin activation and clustering, which in turn supports more force transmission. This positive feedback underlies the maturation of focal adhesions from nascent adhesions (~100 nm) into mature focal adhesions (~1–5 µm).

SECTION 5

Integrin Subfamilies & Ligand Specificity

The 24 mammalian integrins can be organized into functional subfamilies based on their β-subunit usage, ligand specificity, and tissue distribution. Understanding this classification is essential for predicting how specific integrins contribute to different physiological and pathological processes. The major groupings include the RGD-binding integrins, the collagen-binding integrins, the laminin-binding integrins, and the leukocyte-specific integrins (β₂ family).

Subfamily	Key Integrins	Primary ECM Ligands	Biological Role
RGD-binding	α₅β₁, αVβ₃, αIIbβ₃	Fibronectin, vitronectin, fibrinogen	Cell migration, angiogenesis, platelet aggregation
Collagen-binding	α₁β₁, α₂β₁	Collagen I, IV (via αI domain and GFOGER motif)	Tissue integrity, fibrosis, wound contraction
Laminin-binding	α₃β₁, α₆β₄	Laminin-332, laminin-511 in basement membranes	Epithelial polarity, hemidesmosome assembly, skin integrity
Leukocyte (β₂)	αLβ₂ (LFA-1), αMβ₂ (Mac-1)	ICAMs on endothelial cells, complement iC3b	Immune cell extravasation, phagocytosis, T-cell activation

Major integrin subfamilies, representative heterodimers, their ligands, and biological roles

Schematic of a focal adhesion complex. Integrin heterodimers (α in purple, β in cyan) span the membrane and bind ECM proteins such as fibronectin and collagen. On the cytoplasmic side, talin links β-subunit tails to actin stress fibers. Vinculin, paxillin, and FAK are recruited to the complex, creating a signaling hub for mechanotransduction.

The diagram above provides a cross-sectional view of a mature focal adhesion. Note how the integrin heterodimers are clustered rather than uniformly distributed—this clustering is critical for generating the high avidity required for stable adhesion under mechanical stress. The layered architecture of the adhesome—with talin at the integrin-actin interface, vinculin reinforcing the connection, and FAK serving as a phosphorylation-dependent signaling node—allows the focal adhesion to function simultaneously as a structural anchor and a signal transduction platform. Notably, the α₆β₄ integrin assembles an alternative structure called the hemidesmosome, which links laminin in the basement membrane to intermediate filaments rather than actin—an important exception to the general focal adhesion paradigm.

SECTION 6

Worked Example — Integrin Activation & Signaling Analysis

The following worked example walks through a common type of problem encountered in cell biology courses: reasoning about integrin activation states, binding equilibria, and downstream signaling consequences. This integrates concepts from sections 2–5 into a realistic experimental scenario.

Predicting Cell Adhesion Behavior from Integrin Activation Data

1
Step 1 — Identify the Problem

A researcher cultures fibroblasts on fibronectin-coated plates and measures integrin α₅β₁ activity using a conformation-specific antibody (HUTS-4) that only recognizes the extended-open form. In control cells, 15% of surface α₅β₁ is in the active conformation. When cells are treated with Mn²⁺ (a known integrin activator), 85% of surface α₅β₁ becomes active. The K_d for inactive α₅β₁ binding to fibronectin is ~1 mM; for active α₅β₁, it is ~10 nM. Question: By approximately how much does overall fibronectin binding increase upon Mn²⁺ treatment?
2
Step 2 — Define Variables and Assumptions

Let N = total number of surface α₅β₁ molecules. Assume the effective fibronectin concentration on the coated surface is ~1 µM (10⁻⁶ M). We will calculate the fractional occupancy (θ) for each population using the Langmuir isotherm: θ = [L] / (K_d + [L]).
3
Step 3 — Calculate Occupancy for Control Cells

In control cells, 15% of integrins are active and 85% are inactive. For the inactive population (K_d = 10⁻³ M): θ_inactive = 10⁻⁶ / (10⁻³ + 10⁻⁶) ≈ 10⁻⁶ / 10⁻³ = 0.001 (0.1%). For the active population (K_d = 10⁻⁸ M): θ_active = 10⁻⁶ / (10⁻⁸ + 10⁻⁶) ≈ 10⁻⁶ / 10⁻⁶ ≈ 0.99 (99%). Total bound integrins in control = 0.85N × 0.001 + 0.15N × 0.99 = 0.00085N + 0.1485N = 0.149N.

Control: ≈ 14.9% of total integrins are ligand-bound
4
Step 4 — Calculate Occupancy for Mn²⁺-Treated Cells

After Mn²⁺ treatment, 85% are active, 15% remain inactive. Total bound = 0.15N × 0.001 + 0.85N × 0.99 = 0.00015N + 0.8415N = 0.842N.

Mn²⁺-treated: ≈ 84.2% of total integrins are ligand-bound
5
Step 5 — Determine Fold Increase and Biological Implications

Fold increase in binding = 0.842 / 0.149 ≈ 5.7-fold. This ~6-fold increase in integrin occupancy would dramatically enhance cell spreading, focal adhesion assembly, and activation of downstream FAK/Src signaling. In practice, Mn²⁺ treatment is commonly used experimentally to lock integrins in the high-affinity state, and the observed increase in cell adhesion is consistent with this quantitative estimate. Note that the actual increase in total adhesion strength would be even greater because clustering of active, ligand-bound integrins produces cooperative (avidity) effects not captured by the simple Langmuir model.

Overall fibronectin binding increases by approximately 5.7-fold upon Mn²⁺-mediated integrin activation.

SECTION 7

Integrins vs. Other Cell Adhesion Molecules

Integrins are one of several major families of cell adhesion molecules (CAMs). To appreciate their unique properties, it is helpful to compare them with cadherins (primarily mediating cell-cell adhesion), selectins (mediating transient leukocyte rolling), and immunoglobulin superfamily (IgSF) members. Each family has evolved distinct structural features and signaling capabilities optimized for different biological contexts.

Feature	Integrins	Cadherins	Selectins	IgSF CAMs
Structure	αβ heterodimer	Single-pass TM; homophilic dimer	Single-pass TM; lectin domain	Single-pass TM; Ig-like folds
Primary interaction	Cell-matrix (& some cell-cell)	Cell-cell (homophilic)	Cell-cell (heterophilic)	Cell-cell (heterophilic)
Ca²⁺ dependence	Divalent cation (Mg²⁺, Mn²⁺, Ca²⁺ at MIDAS)	Ca²⁺ required for rigidity	Ca²⁺ required for lectin binding	Ca²⁺ independent
Cytoskeletal link	Actin (via talin/vinculin); IF (via plectin for α₆β₄)	Actin (via catenins)	Actin (indirect, via ERM)	Variable
Signaling	Bidirectional (inside-out / outside-in); FAK, Src, MAPK	Wnt / β-catenin; Rho GTPases	Minimal direct signaling	Variable (ICAM-1 signals via Src)
Affinity regulation	Dynamic conformational switching	Lateral clustering (cis-dimers)	Shedding / endocytosis	Expression level changes

Comparison of major cell adhesion molecule families

✦

KEY TAKEAWAY

What makes integrins exceptional among adhesion molecules is their capacity for rapid, reversible affinity regulation through conformational change. While cadherins primarily adjust adhesion by changing surface expression levels (a slower process), integrins can switch between low- and high-affinity states within seconds—analogous to a clutch in a manual transmission that can instantly engage or disengage the drivetrain. This speed is critical for processes like platelet activation during hemostasis, where integrin αIIbβ₃ must shift from inactive to active within seconds of vascular injury to capture fibrinogen and aggregate platelets.

SECTION 8

Connections to Disease & Therapeutic Targeting

The central role of integrins in adhesion, migration, and signaling makes them key players in numerous pathological conditions. Aberrant integrin expression or signaling contributes to cancer metastasis, autoimmune diseases, thrombosis, and fibrosis. Conversely, the accessible extracellular domains of integrins make them attractive drug targets. Understanding integrin biology at the molecular level has directly enabled the development of therapeutics used in clinical practice today.

Disease / Condition	Integrin Involvement	Therapeutic Strategy
Thrombosis	αIIbβ₃ on platelets binds fibrinogen, driving platelet aggregation	Abciximab (ReoPro), eptifibatide, tirofiban block αIIbβ₃ to prevent clot formation
Multiple sclerosis	α₄β₁ (VLA-4) on T cells mediates crossing of the blood-brain barrier	Natalizumab (Tysabri) blocks α₄β₁, preventing immune cell infiltration into the CNS
Inflammatory bowel disease	α₄β₇ directs lymphocyte homing to gut mucosa	Vedolizumab selectively blocks α₄β₇, reducing gut-specific inflammation
Cancer metastasis	Upregulation of αVβ₃ and α₅β₁ promotes tumor cell migration, invasion, and angiogenesis	RGD-mimetic peptides and cilengitide (αVβ₃/αVβ₅ inhibitor) tested in clinical trials for glioblastoma
Glanzmann thrombasthenia	Genetic loss of αIIbβ₃ causes bleeding due to defective platelet aggregation	Platelet transfusion; gene therapy under investigation

Integrin-related diseases and therapeutic approaches

Looking forward, integrin biology intersects with several frontier areas of biomedical research. Mechanobiology studies are revealing how substrate stiffness, sensed through integrins, directs stem cell differentiation—a concept known as durotaxis. In tissue engineering, synthetic RGD-functionalized hydrogels exploit integrin-mediated adhesion to promote cell attachment and tissue regeneration. Additionally, the emerging field of integrin-targeted nanoparticle drug delivery uses RGD-decorated nanocarriers to achieve tumor-specific accumulation by exploiting the overexpression of αVβ₃ on tumor vasculature. These applications underscore how fundamental understanding of integrin structure and function translates directly into biomedical innovation.

💡

From Bench to Bedside

The anti-platelet drug eptifibatide is a cyclic heptapeptide derived from the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). It mimics the RGD motif and competitively blocks fibrinogen binding to αIIbβ₃ on platelets. This is a striking example of how understanding integrin-ligand recognition at the molecular level—specifically the geometry of the RGD-binding pocket—enabled rational drug design from a natural product template.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

Explain why the term integrin was chosen to describe these receptors. What two structural/functional domains does the name reference, and how does the heterodimeric architecture enable the integrating function?

Show answer

The name integrin reflects the receptor's role in integrating the extracellular matrix with the intracellular cytoskeleton. The extracellular headpiece, formed by the α and β subunits together, binds ECM ligands such as fibronectin or collagen, while the short cytoplasmic tails of both subunits recruit adaptor proteins like talin and kindlin that physically link the receptor to actin filaments. The heterodimeric architecture is essential because the α subunit contributes ligand specificity through its β-propeller domain, while the β subunit provides the primary connection to the cytoskeleton via its cytoplasmic tail. Neither subunit alone can accomplish both functions, so the αβ pairing is required to bridge the extracellular and intracellular compartments.

Question 2: BASIC CALCULATION

An integrin in its inactive conformation has a K_d of 500 µM for its ECM ligand. After talin-mediated activation, the K_d drops to 50 nM. Using the Langmuir isotherm (θ = [L] / (K_d + [L])), calculate the fractional occupancy of the integrin in each state when the effective ligand concentration is 5 µM.

Show answer

For the inactive state: θ = 5 µM / (500 µM + 5 µM) = 5 / 505 ≈ 0.0099, or about 1.0% occupancy. For the active state: θ = 5 µM / (0.05 µM + 5 µM) = 5 / 5.05 ≈ 0.990, or about 99.0% occupancy. The conformational shift from inactive to active thus transforms the integrin from essentially unoccupied to nearly saturated at the same ligand concentration, representing a ~100-fold change in occupancy. This illustrates how a 10,000-fold change in K_d acts as a molecular switch at physiological ligand concentrations.

Question 3: INTERMEDIATE

A researcher transfects fibroblasts with a dominant-negative talin construct that lacks the integrin-binding FERM domain but retains the actin-binding rod domain. Predict the effects on: (a) integrin conformational activation, (b) focal adhesion formation, and (c) cell migration on fibronectin. Justify each prediction with specific molecular mechanisms.

Show answer

(a) The dominant-negative talin would compete with endogenous talin for binding partners but cannot engage the β-integrin cytoplasmic tail (since it lacks the FERM domain). This would impair inside-out signaling, keeping most integrins in the bent-closed, low-affinity conformation and reducing the fraction of active integrins on the cell surface. (b) Focal adhesion formation would be severely compromised because talin binding to the β tail is the critical nucleating event for focal adhesion assembly. Without functional talin-integrin coupling, vinculin, paxillin, and FAK recruitment would be disrupted, preventing the maturation of nascent adhesions into stable focal adhesions. The actin-binding rod domain alone cannot rescue this defect because it is not tethered to the membrane. (c) Cell migration on fibronectin would be significantly reduced because migration requires a cycle of adhesion formation at the leading edge and adhesion disassembly at the trailing edge. Without proper integrin activation and focal adhesion assembly, cells would lack the traction forces needed for directed locomotion.

Question 4: APPLIED

Tissue engineers are designing a synthetic hydrogel scaffold for cartilage repair. They want chondrocytes to adhere and maintain their differentiated phenotype. The available options are: (A) coating the scaffold with a linear RGD peptide, (B) incorporating a cyclic RGDfK peptide that targets αVβ₃, or (C) functionalizing with a GFOGER peptide that targets collagen-binding integrins (α₂β₁). Which strategy is most appropriate, and why? Consider both adhesion and signaling consequences.

Show answer

Option (C) is the most appropriate strategy. Chondrocytes in native cartilage reside in a collagen type II-rich matrix and primarily use collagen-binding integrins (α₂β₁, α₁β₁) for adhesion and signaling. The GFOGER peptide mimics the collagen triple-helix recognition motif and would engage these native integrins, promoting adhesion and downstream signaling pathways (such as SOX9-mediated transcription) that support the chondrocyte phenotype. Option (A) is suboptimal because linear RGD peptides are prone to proteolytic degradation and may engage multiple RGD-recognizing integrins non-specifically. Option (B) is problematic because αVβ₃ engagement is associated with pro-angiogenic and pro-migratory signaling more typical of mesenchymal or endothelial cells; it could promote chondrocyte de-differentiation toward a fibroblastic phenotype. The key insight is that integrin-mediated outside-in signaling is not merely adhesive—it actively regulates gene expression, so the choice of integrin engaged determines the cellular response.

Question 5: CRITICAL THINKING

Integrins exhibit catch-bond behavior, where moderate tensile force increases bond lifetime. In contrast, most receptor-ligand interactions follow slip-bond kinetics (force decreases bond lifetime). Propose a mechanistic explanation for how the same integrin-ligand pair can exhibit catch-bond behavior at low forces and slip-bond behavior at high forces. In your answer, consider the structural basis (conformational changes in the integrin headpiece) and the thermodynamic/kinetic landscape (two-state energy barrier model).

Show answer

The biphasic catch-to-slip bond behavior can be explained by a two-pathway dissociation model. At zero force, the integrin-ligand complex can dissociate along a fast pathway associated with the bent or partially extended conformation, where the ligand-binding pocket is not fully engaged. When moderate tensile force is applied along the integrin long axis, it favors the extended-open conformation, which locks the ligand more deeply into the binding pocket (the headpiece opens, and the α₇ helix in the βI domain shifts downward). This force-induced conformational change diverts dissociation from the fast pathway to a slow pathway with a higher energy barrier, effectively increasing bond lifetime—the hallmark of catch-bond behavior. However, at very high forces, the mechanical energy becomes sufficient to overcome even the high-energy barrier of the slow pathway, and the bond ruptures rapidly—reverting to classic slip-bond kinetics. Structurally, the allosteric coupling between the hybrid domain swing-out and the MIDAS (metal ion-dependent adhesion site) coordination of the ligand's aspartate residue provides the physical basis for this force-dependent conformational selection. This two-state model is supported by steered molecular dynamics simulations and single-molecule force spectroscopy data.

SUMMARY

Summary — Integrins and Cell-Matrix Adhesion

Summary

Integrins are heterodimeric transmembrane receptors (one α + one β subunit) that physically link the extracellular matrix to the intracellular actin cytoskeleton. They exist in three conformational states—bent-closed (inactive), extended-closed (primed), and extended-open (active)—allowing rapid, reversible regulation of ligand-binding affinity. Inside-out activation is triggered by talin and kindlin binding to the β-subunit cytoplasmic tail, while outside-in signaling through FAK and Src kinases relays information about ECM composition and mechanical properties into the cell.

Activated integrins cluster into focal adhesions—multi-protein signaling hubs that connect integrins to actin stress fibers and enable mechanotransduction. The 24 mammalian integrins are classified by ligand specificity into RGD-binding, collagen-binding, laminin-binding, and leukocyte-specific (β₂) subfamilies. Clinically, integrins are targets of FDA-approved drugs for thrombosis (abciximab, eptifibatide), multiple sclerosis (natalizumab), and inflammatory bowel disease (vedolizumab). Their unique catch-bond behavior and role in durotaxis continue to make integrins a central topic in mechanobiology and translational medicine.